The first of several expected vaccine options for preventing RSV in older adults has been approved by the FDA.
Arexvy is approved for people ages 60 and older, and trials showed it reduced the risk of life-threatening complications from RSV, such as pneumonia and bronchitis, by as much as 94%.
Between 60,000 and 120,000 people are hospitalized each year for RSV, and the virus plays a role in up to 10,000 annual deaths of people ages 65 and older, the FDA noted, citing CDC data. RSV was one of the three respiratory illnesses that played a prominent role in this past winter’s “tripledemic.”
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA approves world's first RSV vaccine, a shot for adults ages 60 and upBREAKING: FDA approves the world's first respiratory syncytial virus, or RSV, vaccine made by pharmaceutical giant GSK.
Weiterlesen »
FDA approves first vaccine for RSV, a moment six decades in the making | CNNAfter a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way.
Weiterlesen »
FDA approves first RSV vaccine to protect older adultsUp to 10,000 deaths and 160,000 hospitalizations a year are caused by RSV.
Weiterlesen »
FDA approves world’s first RSV vaccine, a shot for older adultsIn a late-stage clinical trial, the single-dose shot lowered the risk of symptomatic illness by 83% and of severe illness by 94%.
Weiterlesen »
US FDA approves first RSV vaccine from GSKThe U.S. Food and Drug Administration has approved GSK Plc's respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people.
Weiterlesen »